Entity

Time filter

Source Type

Saint-Priest-en-Jarez, France

Fournel P.,Institute Of Cancerologie Lucien Neuwirth
Revue des Maladies Respiratoires Actualites | Year: 2014

A combination of chemotherapy and radiotherapy is the standard treatment for limited stage small cell lung cancer. We are waiting for results from randomized trials which will shed light on the modalities of radiotherapy. © 2014 Elsevier Masson SAS. Source


Kast R.E.,IIAIGC Headquarters | Boockvar J.A.,Cornell College | Bruning A.,Ludwig Maximilians University of Munich | Cappello F.,University of Palermo | And 24 more authors.
Oncotarget | Year: 2013

To improve prognosis in recurrent glioblastoma we developed a treatment protocol based on a combination of drugs not traditionally thought of as cytotoxic chemotherapy agents but that have a robust history of being well-tolerated and are already marketed and used for other non-cancer indications. Focus was on adding drugs which met these criteria: a) were pharmacologically well characterized, b) had low likelihood of adding to patient side effect burden, c) had evidence for interfering with a recognized, well-characterized growth promoting element of glioblastoma, and d) were coordinated, as an ensemble had reasonable likelihood of concerted activity against key biological features of glioblastoma growth. We found nine drugs meeting these criteria and propose adding them to continuous low dose temozolomide, a currently accepted treatment for relapsed glioblastoma, in patients with recurrent disease after primary treatment with the Stupp Protocol. The nine adjuvant drug regimen, Coordinated Undermining of Survival Paths, CUSP9, then are aprepitant, artesunate, auranofin, captopril, copper gluconate, disulfiram, ketoconazole, nelfinavir, sertraline, to be added to continuous low dose temozolomide. We discuss each drug in turn and the specific rationale for use- how each drug is expected to retard glioblastoma growth and undermine glioblastoma's compensatory mechanisms engaged during temozolomide treatment. The risks of pharmacological interactions and why we believe this drug mix will increase both quality of life and overall survival are reviewed. Source


Pillet S.,Jean Monnet University | Roblin X.,Jean Monnet University | Cornillon J.,Institute Of Cancerologie Lucien Neuwirth | Mariat C.,Jean Monnet University | Pozzetto B.,Jean Monnet University
Expert Review of Anti-Infective Therapy | Year: 2014

Cytomegalovirus (CMV), a member of the Herpesviridae family, is worldwide distributed. After the primary infection, CMV induces a latent infection with possible reactivation(s). It is responsible for severe to life-threatening diseases in immunocompromised patients and in foetuses and newborns of infected mothers. For monitoring CMV load, classical techniques based on rapid culture or pp65 antigenemia are progressively replaced by quantitative nuclear acid tests (QNAT), easier to implement and standardize. A large variety of QNAT are available from laboratory-developed assays to fully-automated commercial tests. The indications of CMV quantification include CMV infection during pregnancy and in newborns, and viral surveillance of grafted and non-grafted immunocompromised patients, patients with bowel inflammatory diseases and those hospitalised in intensive care unit. A close cooperation between virologists and clinicians is essential for optimizing the benefit of CMV DNA monitoring. © 2014 Informa UK Ltd. Source


Introduction. -In Europe, breast cancer is the most common cancer among women. His treatment (TTT) can have a significant impact on daily life.Aims. -Explore the experienced short-Term side effects (SE) of chemotherapy and hormonal therapy by women themselves, the information delivered and the place of the general practitioner (GP).Method. -Qualitative study by individual interview, conducted from January to May 2015, with 14 women followed for no metastatic breast cancer after chemotherapy and possible initiation of hormone therapy, at the Cancer Institute of the Loire (France).Results. -The SE of chemotherapy, except vomiting, have appeared very trying (fatigue, pains oral and cutaneous involvement), punctuated and accentuated by the cures. They were resounding on daily life, requiring family or professional assistance. Falling dander, considered stigmatizing, violated the person and femininity. The women have estimated to be well informed. They had appreciated the initial response of the pivot nurse. The least expected SE of hormone therapy, hot flashes and articular pains might limit activities. To counteract these side effects, mostly accepted to prevent recidivism, a remedy for complementary therapies was frequent. The GP was solicited for some SE, sometimes for complementary medicine (CM).Conclusion. -Over the cures, women suggested support meetings, a more sustainable action of the pivot nurse, a better attention to their complaints and a more personalized information. The development of TTT less EI provider was desired. The effect of CM on SE should be explored. © 2016 Société française de pharmacologie et de thérapeutique. Source


This article proposes a psychodynamic reflection of the paradox that we experience as psychologists during our work with cancer patients who were caught up in between life and death. This surprising paradox would emanate from many and powerful movements of counter transference which we have to identify and to question. Indeed, these movements would often result in some intuitive thoughts of having spent a good or a bad day at work. However, although spending a bad day in oncology could seem quite normal and expected because of the inevitably anxietyprovoking report to critically ill patients, coming back home happy and satisfied from our work as psychologists with these same patients might seem more original. So, the paradox would be this one: 1) the central node — the lethal disease—would remain the red wire of a great and constant mobilization of empathy and shoring, and therefore would generate the risk of burnout, and even professional suffering; 2) however, in parallel, the diversity of issues and psychic resources of our ill patients would feed an immense reserve of potentials and prospects, which are real engines of psychic work in our therapeutic spaces, and so many sources of satisfaction and fulfillment in our psychologists work in oncology. © 2015, Springer-Verlag France. Source

Discover hidden collaborations